Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Top Cited Papers
- 15 October 2007
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 58 (1), 106-115
- https://doi.org/10.1016/j.jaad.2007.09.010
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension studyJournal of the American Academy of Dermatology, 2006
- Efficacy and Safety Observed During 24 Weeks of Efalizumab Therapy in Patients With Moderate to Severe Plaque PsoriasisArchives of Dermatology, 2005
- Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trialArthritis & Rheumatism, 2004
- Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment DissatisfactionJournal of Investigative Dermatology Symposium Proceedings, 2004
- A Randomized Trial of Etanercept as Monotherapy for PsoriasisArchives of Dermatology, 2003
- An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque PsoriasisArchives of Dermatology, 2003
- Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor ? receptor IgG1-Fc fusion complex therapyJournal of the American Academy of Dermatology, 2001
- The effect of severe psoriasis on the quality of life of 369 patientsBritish Journal of Dermatology, 1995
- Localization of tumour necrosis factor-alpha (TNF-α) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptorClinical and Experimental Immunology, 1993
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978